Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation (Nasdaq: CTSO) on July 30, 2019. The filing discloses the execution of Amended and Restated Executive Employment Agreements with three key officers: Dr. Phillip P. Chan (CEO), Vincent Capponi (COO), and Kathleen P. Bloch (CFO). The agreements are retroactively effective as of January 1, 2019, with an initial term of three years and automatic one-year renewals thereafter.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
| Executive | Role | Annual Base Salary | Travel Reimbursement |
|---|---|---|---|
| Dr. Phillip P. Chan | CEO | $438,000 | Up to $12,000 |
| Vincent Capponi | COO | $363,540 | Not specified |
| Kathleen P. Bloch | CFO | $323,025 | Not specified |
Material Changes and Severance Provisions
The primary material change is the formalization of employment terms and severance packages for the executive team. Key provisions include:
- Termination without Cause/Good Reason:
- CEO: 12 months base salary severance.
- COO: 15 months base salary severance.
- CFO: 9 months base salary severance.
- Change in Control (within 12 months): All three executives are entitled to 18 months of base salary severance payable in a lump sum.
- Stock Acceleration: Termination under specified circumstances triggers the acceleration of vesting for all service-vesting stock options, restricted stock units, and restricted stock.
- Non-Compete: All executives are subject to non-competition and non-solicitation covenants for 12 months following the termination of their employment.
Guidance, Risks, and Contingencies
The filing does not contain financial guidance, outlook, or management commentary regarding business operations. However, it outlines specific contingencies:
- Golden Parachutes: Payments are subject to Section 280G of the Internal Revenue Code. Executives will receive the lesser of the full amount or the 280G Threshold Amount, unless the full amount provides a greater net after-tax benefit.
- Retirement Provisions: The COO and CFO agreements include specific provisions allowing for extended stock option exercise periods (18 months) if they retire at age 65 or older with six months' notice.
Investor Verification Checklist
- Verify the total potential cash liability for severance in the event of a Change in Control for all three executives.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the full legal text of the employment agreements.
- Assess the impact of the 12-month non-compete clauses on the company's ability to hire or be hired by competitors.
- Confirm the number of outstanding stock options and restricted stock units held by each executive to evaluate the cost of acceleration.